DC10930 |
Tianeptinaline |
Tianeptinaline is a class I HDAC-selective, brain penetrant analogue of tianeptine with IC50 of 0.24, 0.12 and 0.155 uM for HDAC1, 2 and 3 respectively, does not inhibit HDAC6. |
|
DC10931 |
Tianeptinostat |
Tianeptinostat is a class I HDAC inhibitor with IC50 of 28, 33 and 51 nM for HDAC1, 2 and 3, respectively, also inhibits HDAC6 (IC50=1.6 nM) but not HDAC5 (IC50>80 uM). |
|
DC10478 |
Tinostamustine(EDO-S101)
Featured
|
Tinostamustine is the first representative of the A-DAC principle, a new approach in chemotherapy that uses fusion technology to combine an alkylating agent with a pan-histone deacetylase inhibitor (HDAC) to simultaneously damage DNA and block damage repa |
|
DC10210 |
TMP195
Featured
|
TMP195 is the most potent and selective class IIa HDAC inhibitor. |
|
DC7716 |
TMP269
Featured
|
TMP269 is a novel and selective class IIa histone deacetylase inhibitor with IC50s of 126/80/36/9 nM for HDAC 4/5/7/9, respectively; 20-400 fold selectivity over class1 HDACs. |
|
DC8134 |
Trichostatin A (TSA)
Featured
|
Trichostatin A (TSA) is a selective and potent HDAC inhibitor with IC50 of ~1.8 nM; HDAC8 is the only known member of the HDAC-family that is not affected by TSA. |
|
DC5178 |
Tubacin (BML-GR362)
Featured
|
Tubacin is a selective inhibitor of HDAC6 via inhibition of the second deacetylase domain (DD2). |
|
DC6304 |
Tubastatin A
Featured
|
Tubastatin A is a potent and selective HDAC6 inhibitor with IC50 of 15 nM. It is selective against all the other isozymes (1000-fold) except HDAC8 (57-fold). |
|
DC6303 |
Tubastatin A HCl
Featured
|
Tubastatin A is a potent and selective HDAC6 inhibitor with IC50 of 15 nM. It is selective against all the other isozymes (1000-fold) except HDAC8 (57-fold). |
|
DC8663 |
UF010
Featured
|
UF010 is a potent and selective HADC inhibitor with IC50 ~0.06 μM, 0.1 μM, 0.5 μM and 1.5 μM for HDACs 3, 2, 1 and 8, respectively. It has > 6-fold selectivity over other HDACs. |
|
DC8252 |
Vorinostat (SAHA)
Featured
|
Vorinostat (SAHA) is an HDAC1/3 inhibitor with IC50 of ~10 nM. |
|
DC10172 |
WT-161 |
WT-161 is a potent and selective HDAC6 inhibitor with an IC50 of 0.40 nM. |
|
DC11074 |
Alteminostat |
|
|
DC3110 |
CUDC-907 (PI3K/HDAC InhibitorI)
Featured
|
CUDC-907 (PI3K/HDAC Inhibitor I) is a dual PI3K and HDAC inhibitor for PI3Kɑ, HDAC1, HDAC2, HDAC3 and HDAC10 with IC50 of 19 nM, 1.7 nM, 5 nM, 1.8 nM and 2.8 nM, respectively. |
|
DC39111 |
Tubastatin A TFA |
Tubastatin A TFA (Tubastatin A trifluoroacetate salt) is a potent and selective HDAC6 inhibitor with IC50 of 15 nM in a cell-free assay. It is selective against all the other isozymes (1000-fold) except HDAC8 (57-fold). Tubastatin A promotes autophagy and increases apoptosis. |
|
DC40117 |
Tucidinostat D4 |
Tucidinostat D4 (Chidamide D4) is the deuterium labeled Tucidinostat. Tucidinostat is a potent and orally bioavailable HDAC enzymes class I (HDAC1/2/3) and class IIb (HDAC10) inhibitor, with IC50s of 95, 160, 67 and 78 nM, respectively. |
|
DC41319 |
Psammaplin A |
Psammaplin A, a marine metabolite, is a potent inhibitor of HDAC and DNA methyltransferases. Psammaplin A ia a highly potent and selective DAC1 inhibitor with an IC50 of 0.9 nM. Psammaplin A possess the antimicrobial effect on the Gram-positive bacteria and inhibits DNA synthesis and DNA gyrase activity. Antitumor Activity. |
|
DC41974 |
Ac-Arg-Gly-Lys(Ac)-AMC |
Ac-Arg-Gly-Lys(Ac)-AMC is a substrate for HDAC. |
|
DC44009 |
FNDR-20123 free base |
FNDR-20123 free base is an orally active, safe and a first-in-class anti-malarial HDAC inhibitor with IC50s of 31 nM and 3 nM for Plasmodium and human HDAC, respectively. FNDR-20123 free base exerts anti-malarial activity against Plasmodium falciparum asexual stage (IC50=41 nM) and sexual blood stage (IC50=190 nM for male gametocytes). FNDR-20123 free base inhibits HDAC1, HDAC2, HDAC3, HDAC6, and HDAC8 (IC50=25, 29, 2, 11, and 282 nM, respectively) and inhibits Class III HDAC isoforms at nanomolar concentrations. |
|
DC44140 |
FNDR-20123 |
FNDR-20123 is an orally active, safe and a first-in-class anti-malarial HDAC inhibitor with IC50s of 31 nM and 3 nM for Plasmodium and human HDAC, respectively. FNDR-20123 exerts anti-malarial activity against Plasmodium falciparum asexual stage (IC50=41 nM) and sexual blood stage (IC50=190 nM for male gametocytes). FNDR-20123 inhibits HDAC1/2/3/6/8 (IC50=25/29/2/11/282 nM) and inhibits Class III HDAC isoforms at nanomolar concentrations. |
|
DC45388 |
Pomiferin |
Pomiferin (NSC 5113) acts as an potential inhibitor of HDAC, with an IC50 of 1.05 μM, and also potently inhibits mTOR (IC50, 6.2 µM). |
|
DC46045 |
KA2507 hydrochloride |
KA2507 hydrochloride is a potent and highly selective inhibitor of HDAC6 (IC50=2.5 nM) with no significant toxicities. KA2507 hydrochloride shows antitumor efficacy and immune modulatory effects. |
|
DC47268 |
Ivaltinostat formic |
Ivaltinostat (CG-200745) formic is a potent HDAC inhibitor which has the hydroxamic acid moiety to bind zinc at the bottom of catalytic pocket. Ivaltinostat formic inhibits deacetylation of histone H3 and tubulin. Ivaltinostat formic induces the accumulation of p53, promotes p53-dependent transactivation, and enhances the expression of MDM2 and p21 (Waf1/Cip1) proteins. Ivaltinostat formic induces apoptosis. |
|
DC47624 |
HDAC1/2-IN-3 |
HDAC1/2-IN-3 is a HDAC1 and HDAC2 inhibitor with IC50 values 0-5 and 5-10 nM, respectively. |
|
DC47625 |
Dihydrochlamydocin |
Dihydrochlamydocin is a Putative HDAC inhibitor. |
|
DC47626 |
HDAC/BET-IN-1 |
HDAC/BET-IN-1 displays submicromolar inhibitory activity against HDAC1 and 6 (IC50 = 0.163 μM and 0.067 μM), and BRD4 (Ki = 0.076 μM), and possess potent antileukemia activity. |
|
DC47627 |
QTX125 TFA |
QTX125 TFA is a potent and highly selective HDAC6 inhibitor. QTX125 TFA exhibits excellent selectivity over other HDACs. QTX125 has antitumor effects. |
|
DC48137 |
HDAC-IN-26 |
HDAC-IN-26 is a highly selective class I HDAC inhibitor with an EC50 value of 4.7 nM. |
|
DC48525 |
Phenylbutyrate |
Phenylbutyrate is a potent histone deacetylases (HDACs) inhibitor. Phenylbutyrate can be used for urea cycle disorder research. |
|
DC48761 |
XP5 |
XP5 is a potent, orally active HDAC6 inhibitor with an IC50 of 31 nM. XP5 displays high antiproliferative activity against various cancer cell lines including the HDACi-resistant YCC3/7 gastric cancer cells (IC50=0.16-2.31 μM). XP5 enhances antitumor immunity when combined with a PD-L1 inhibitor in melanoma. |
|